Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New R&D Tax Incentives Enough To Support Korean Drug Development?

This article was originally published in PharmAsia News

Executive Summary

The South Korean government has unveiled more details of new R&D tax support for emerging industries, including bio-health care, to encourage research spending by the pharma sector. But a local industry association suggests the government may also have to think twice about an existing R&D tax incentive system that provides incremental reductions and gives preferential benefits to smaller firms.

You may also be interested in...



Korean Health Tech Blueprint Highlights Precision, Regenerative Medicine

South Korea unveils its first comprehensive plan for the overall development of the health care industry, with a focus on developing novel therapies for rare and incurable diseases, precision and regenerative medicine, and customized health management systems, with the aims of improving care, controlling costs, and raising global industry competitiveness.

Inspection Delay Puts Back Hanmi/Spectrum’s Rolontis

US FDA defers action on Spectrum’s approval application for neutropenia candidate Rolontis due to pandemic-related difficulties inspecting partner Hanmi’s plant. The action date has been put back by around four months although the companies stress no CRL has been issued. 

Voronoi’s Brain-Permeable NSCLC Candidate Attracts ORIC To Major Deal

Through a licensing-out deal with ORIC for its EGFR/HER2 exon-20 inhibitor, South Korea's Voronoi hopes to gain from its new partner's commercialization experience in NSCLC. The alliance aims to build a potentially best-in-class presence in a competitive landscape.

Topics

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel